Literature DB >> 10858179

Effect of hepatitis G virus infection on progression of HIV infection in patients with hemophilia. Multicenter Hemophilia Cohort Study.

A E Yeo1, A Matsumoto, M Hisada, J W Shih, H J Alter, J J Goedert.   

Abstract

BACKGROUND: Infection with hepatitis G virus (HGV), also known as GB virus C, is prevalent but is not known to be associated with any chronic disease. Infection with HGV may affect the risk for AIDS in HIV-infected persons.
OBJECTIVE: To compare AIDS-free survival in patients with and those without HGV infection during 16 years of follow-up after HIV seroconversion.
DESIGN: Subanalysis of a prospective cohort study.
SETTING: Comprehensive hemophilia treatment centers in the United States and Europe. PATIENTS: 131 patients with hemophilia who became HIV-positive between 1978 and 1985. MEASUREMENTS: Age, CCR5 genotype, HIV and HCV viral loads, CD4+ and CD8+ lymphocyte counts, and 12-year AIDS-free survival by HGV positivity (viremia [RNA] or anti-E2 antibodies).
RESULTS: Compared with HGV-negative patients, the 60 HGV-positive patients (46%), including 22 who were positive for HGV RNA, had higher CD4+ lymphocyte counts (difference, 211 cells/mm3 [95% Cl, 88 to 333 cells/mm3]) and 12-year AIDS-free survival rates (68% compared with 40%; rate difference, 1.9 per 100 person-years [Cl, -0.3 to 4.2 per 100 person-years]), despite similar ages and HIV viral loads. In multivariate proportional hazards models, risk for AIDS was 40% lower for HGV-positive patients independent of age, HIV and HCV viral loads, CD4+ and CD8+ lymphocyte counts, and CCR5 genotype.
CONCLUSIONS: Patients with past or current HGV infection have higher CD4+ lymphocyte counts and better AIDS-free survival rates. The mechanism of this association is unknown.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10858179     DOI: 10.7326/0003-4819-132-12-200006200-00006

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  25 in total

1.  Clearance of GB virus C during highly active antiretroviral therapy and course of HIV disease progression in HIV-infected patients with hemophilia.

Authors:  H Toyoda; T Honda; Y Katano; H Goto; J Takamatsu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-09       Impact factor: 3.267

2.  Human Pegivirus infection and lymphoma risk and prognosis: a North American study.

Authors:  Angelo Fama; Jinhua Xiang; Brian K Link; Cristine Allmer; Donna Klinzman; Andrew L Feldman; Grzegorz S Nowakowski; Mark Liebow; Melissa C Larson; Matthew J Maurer; Stephen M Ansell; Anne J Novak; Yan W Asmann; Susan L Slager; Timothy G Call; Thomas M Habermann; James R Cerhan; Jack T Stapleton
Journal:  Br J Haematol       Date:  2018-05-29       Impact factor: 6.998

3.  Prevalence and genotypic variability of TTV in HIV-infected patients.

Authors:  K E Sherman; S D Rouster; J Feinberg
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

Review 4.  GBV-C: state of the art and future prospects.

Authors:  Maria Teresa Maidana Giret; Esper Georges Kallas
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

5.  Noninfectious papilloma virus-like particles inhibit HIV-1 replication: implications for immune control of HIV-1 infection by IL-27.

Authors:  J Mohamad Fakruddin; Richard A Lempicki; Robert J Gorelick; Jun Yang; Joseph W Adelsberger; Alfonso J Garcia-Pineres; Ligia A Pinto; H Clifford Lane; Tomozumi Imamichi
Journal:  Blood       Date:  2006-10-26       Impact factor: 22.113

Review 6.  Role of GB virus C in modulating HIV disease.

Authors:  Carolynne Schwarze-Zander; Jason T Blackard; Juergen K Rockstroh
Journal:  Expert Rev Anti Infect Ther       Date:  2012-05       Impact factor: 5.091

7.  Baboon CD8 T cells suppress SIVmac infection in CD4 T cells through contact-dependent production of MIP-1α, MIP-1β, and RANTES.

Authors:  Veronica Obregon-Perko; Vida L Hodara; Laura M Parodi; Luis D Giavedoni
Journal:  Cytokine       Date:  2018-05-26       Impact factor: 3.861

8.  Effect of primer selection on estimates of GB virus C (GBV-C) prevalence and response to antiretroviral therapy for optimal testing for GBV-C viremia.

Authors:  I E Souza; J B Allen; J Xiang; D Klinzman; R Diaz; S Zhang; K Chaloner; D Zdunek; G Hess; C F Williams; L Benning; J T Stapleton
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

9.  Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.

Authors:  Yvonne Koedel; Kristin Eissmann; Holger Wend; Bernhard Fleckenstein; Heide Reil
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

10.  GB virus C envelope protein E2 inhibits TCR-induced IL-2 production and alters IL-2-signaling pathways.

Authors:  Nirjal Bhattarai; James H McLinden; Jinhua Xiang; Thomas M Kaufman; Jack T Stapleton
Journal:  J Immunol       Date:  2012-07-27       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.